HIVEP2

HIVEP2 Full Name

human immunodeficiency virus type I enhancer binding protein 2

HIVEP2 Introduction

HIVEP2 (human immunodeficiency virus type I enhancer binding protein 2) encodes a large zinc-finger transcription factor belonging to the HIVEP family, characterized by multiple ZAS domains that mediate sequence-specific DNA binding and transcriptional regulation. Originally identified through its ability to bind enhancer elements within the long terminal repeat of Human immunodeficiency virus 1, HIVEP2 is now understood primarily as a regulator of host gene expression rather than a virus-specific factor. Structurally, it contains clustered C2H2-type zinc-finger motifs and regulatory regions that support nuclear localization and interaction with promoter/enhancer elements, particularly κB-like motifs. Comparative analyses of HIVEP paralogs (HIVEP1–3) and homologs such as Schnurri proteins in invertebrates and vertebrates demonstrate strong evolutionary conservation, linking this family to NF-κB–related transcription, TNF signaling, and developmental pathways including TGF-β/Dpp cascades. This conserved architecture provides the mechanistic foundation for HIVEP2's broad regulatory reach, particularly in neural tissues where tightly controlled transcriptional programs govern neuronal differentiation, synaptic maturation, and circuit formation.

Genetic studies over the past decade have established HIVEP2 as a neurodevelopmental disease gene, with recurrent de novo loss-of-function (LOF) and truncating variants identified in individuals with intellectual disability (ID) and global developmental delay. Across independent cohorts, patients harboring protein-truncating HIVEP2 variants consistently present with moderate-to-severe ID, hypotonia, and variable dysmorphic features, supporting haploinsufficiency as the primary pathogenic mechanism. Subsequent reports have expanded the phenotype to include behavioral disturbances, hyperphagia, obesity-related traits, and Angelman-like features in some individuals, illustrating variable expressivity rather than phenotypic contradiction. The convergence of de novo variant status, truncating mutation type, and consistent neurodevelopmental presentation strongly supports a causal relationship. Importantly, no robust counter-evidence disputes the association between HIVEP2 LOF and ID; instead, nuance lies in the breadth of clinical manifestations. The emerging consensus is that HIVEP2-related disorder represents a spectrum condition, anchored by developmental delay and cognitive impairment but modulated by genetic background and possibly environmental factors.

At the molecular level, HIVEP2 appears to regulate transcriptional networks critical for brain development and neuronal function. Functional analyses suggest that HIVEP2 influences NF-κB–responsive genes, c-Myc–related pathways, and neuronal signaling programs, consistent with its DNA-binding capacity at κB-like motifs. Beyond inflammatory signaling, evidence indicates that HIVEP2 modulates dopaminergic gene expression, including regulation of SLC6A3 (DAT), implicating it in circuits relevant to cognition, behavior, and neuropsychiatric phenotypes. Animal models of related Schnurri proteins further demonstrate that disruption of this transcription factor family alters dendritic spine morphology and synaptic development, offering a plausible mechanistic bridge between transcriptional dysregulation and cognitive impairment. Collectively, the literature supports a model in which HIVEP2 haploinsufficiency perturbs coordinated transcriptional programs during neurodevelopment, leading to altered neuronal connectivity and intellectual disability. Clinically, HIVEP2 should be considered in individuals with unexplained ID, especially when exome sequencing reveals de novo truncating variants. Continued investigation into genome-wide binding targets, cell-type–specific regulatory roles, and downstream pathway interactions will refine understanding of HIVEP2's function and may ultimately inform targeted therapeutic strategies for HIVEP2-associated neurodevelopmental disorders.

Alternate Names for HIVEP2

HIVEP2; human immunodeficiency virus type I enhancer binding protein 2; SHN2; ZAS2; MBP-2; MIBP1; ZNF40B; HIV-EP2; transcription factor HIVEP2; Schnurri-2; MHC binding protein-2; MHC-binding protein 2; c-myc intron binding protein 1; human immunodeficiency virus type I enhancer-binding protein 2;

• 1. Dürr U., et al. Isolation and characterization of the Xenopus HIVEP gene family. European Journal of Biochemistry. 2004;271(6):1135–1144.
  2. Goldsmith H., et al. Expanding the phenotype of intellectual disability caused by HIVEP2 variants. American Journal of Medical Genetics Part A. 2019;179(9):1872–1877.
  3. Nakao A., et al. Immature morphological properties in subcellular-scale structures in the dentate gyrus of Schnurri-2 knockout mice: a model for schizophrenia and intellectual disability. Molecular Brain. 2017;10(1).